文献速递糖尿病肥胖与代谢综合征

2型糖尿病患者循环脂联素浓度升高可预测新发癌症——脂联素悖论

Higher Circulating Adiponectin Concentrations Predict Incident Cancer in Type 2 Diabetes - The Adiponectin Paradox.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

研究纳入香港西区糖尿病登记处5658例2型糖尿病患者,前瞻性分析基线血清脂联素与新发癌症及癌症死亡的关系。中位随访6.5年,7.53%发生癌症、3%发生癌症死亡;脂联素每翻倍,新发癌症HR 1.19(95%CI 1.05-1.35,P=0.006),癌症死亡HR 1.23(95%CI 1.03-1.47,P=0.024)。

要点

  • 2型糖尿病患者中,新发癌症者基线脂联素9.8 μg/mL vs 无癌症者9.1 μg/mL(P<0.001)。
  • 癌症死亡者基线脂联素11.5 μg/mL vs 无癌症死亡者9.3 μg/mL(P<0.001)。
  • 脂联素每翻倍,新发癌症HR 1.19(95%CI 1.05-1.35),癌症死亡HR 1.23(95%CI 1.03-1.47)。

核心结论

  • 在2型糖尿病患者中,较高的血清脂联素浓度与新发癌症及癌症死亡独立相关,提示脂联素悖论除心血管和肾脏疾病外也可见于另一主要糖尿病并发症。

研究设计与样本

  • 前瞻性队列研究,纳入香港西区糖尿病登记处5658例2型糖尿病患者,测量基线血清脂联素浓度。
  • 采用多变量Cox回归分析脂联素与新发癌症及癌症死亡的关系,风险比按血清脂联素浓度每翻倍计算。

主要发现

  • 中位随访6.5年,7.53%的参与者发生癌症,3%发生癌症死亡。
  • 新发癌症者血清脂联素为9.8 μg/mL,无新发癌症者为9.1 μg/mL(P < 0.001)。
  • 癌症死亡者血清脂联素为11.5 μg/mL,无癌症死亡者为9.3 μg/mL(P < 0.001)。
  • 多变量分析中,血清脂联素浓度与新发癌症独立相关(HR 1.19;95%CI 1.05-1.35;P = 0.006)。
  • 多变量分析中,血清脂联素浓度与癌症死亡独立相关(HR 1.23;95%CI 1.03-1.47;P = 0.024)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the beneficial cardiometabolic effects of adiponectin demonstrated in preclinical studies, paradoxically higher circulating adiponectin concentrations have been found in epidemiological studies to be associated with incident cardiovascular events, renal outcomes, and mortality in patients with diabetes. On the other hand, diabetes is also associated with an increased risk of cancer. Here, we investigated prospectively the association between circulating adiponectin concentrations and incident cancer using a cohort of exclusively individuals with type 2 diabetes. MATERIALS AND METHODS: Baseline serum adiponectin concentrations were measured in 5658 participants recruited from the Hong Kong West Diabetes Registry. The associations of circulating adiponectin concentrations with incident cancer and cancer-related deaths were evaluated using multivariable Cox regression analysis, with hazard ratio (HR) for adiponectin referring to the respective risk per doubling of serum adiponectin concentration. RESULTS: Over a median-follow up of 6.5 years, 7.53% and 3% of participants developed cancer and had cancer-related deaths, respectively. Serum adiponectin concentrations were significantly higher in those who had incident cancer (9.8 μg/mL vs 9.1 μg/mL, P < 0.001) and cancer-related deaths (11.5 μg/mL vs 9.3 μg/mL, P < 0.001) compared with those without. Moreover, in multivariable analyses, serum adiponectin concentration was independently associated with both incident cancer (hazard ratio, 1.19; 95% confidence interval, 1.05-1.35; P = 0.006) and cancer-related deaths (hazard ratio, 1.23; 95% confidence interval, 1.03-1.47; P = 0.024). CONCLUSIONS: Higher serum adiponectin concentration was independently associated with incident cancer and cancer-related deaths in type 2 diabetes, indicating that adiponectin paradox can be observed in another major diabetic complication in addition to cardiovascular and kidney diseases.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lee CH, Lui DTW, Cheung CYY, et al. Higher Circulating Adiponectin Concentrations Predict Incident Cancer in Type 2 Diabetes - The Adiponectin Paradox. J Clin Endocrinol Metab. 2020. PMID: 32072163. doi:10.1210/clinem/dgaa075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。